1. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). (September 2015) Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M.S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassel, J.C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F.S.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗